Brooks Laboratories' Q2 FY 2025-26 Quarterly Results

Result Summary

• Brooks Laboratories Ltd reported a 7.3% quarter-on-quarter (QoQ) decrease in its consolidated revenues for the quarter-ended Sep (Q2 FY 2025-26). On a year-on-year (YoY) basis, it witnessed a growth of 13.6%.
• Its expenses for the quarter were down by 6.4% QoQ and up 7.8% YoY.
• The net profit decreased 16.7% QoQ and decreased 301.5% YoY.
• The earnings per share (EPS) of Brooks Laboratories Ltd stood at 2.71 during Q2 FY 2025-26.

Financial Statments for Q2 FY 2025-26

Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results

Company Overview

Brooks Laboratories Ltd is a pharmaceutical company engaged in the manufacturing and sale of pharmaceutical formulations. The company's primary focus is on developing and supplying a wide range of products, including antibiotics, anti-inflammatory drugs, and other therapeutic categories. Brooks Laboratories operates within the pharmaceutical industry, which is subject to regulatory scrutiny and market dynamics such as patent expirations and pricing pressures. Information regarding recent major developments at Brooks Laboratories is not available from the data provided.

Revenue

During the second quarter of the fiscal year 2026 (Q2FY26), Brooks Laboratories Ltd reported a total income of ₹23.84 crores. This represents a decrease of 7.3% compared to the preceding quarter (Q1FY26), where the total income was ₹25.73 crores. However, on a year-over-year basis, there was a 13.6% increase in total income compared to the second quarter of the fiscal year 2025 (Q2FY25), where the income was ₹20.99 crores. These figures highlight the company's ability to generate increased revenue over the previous year while experiencing a decline in revenue on a quarterly basis.

Profitability

In terms of profitability, Brooks Laboratories Ltd recorded a profit before tax of ₹2.24 crores in Q2FY26. This marks a decrease of 15.5% compared to the previous quarter (Q1FY26), where the profit before tax was ₹2.65 crores. On a year-over-year basis, the profit before tax increased significantly by 133.3% from ₹0.96 crores in Q2FY25. While the company did not incur any tax expenses in any of the compared periods, the profit after tax amounted to ₹7.98 crores in Q2FY26, which denotes a decline of 16.7% from Q1FY26 and a substantial increase from a loss of ₹3.96 crores in Q2FY25.

Operating Metrics

The company's total expenses for Q2FY26 stood at ₹21.60 crores, reflecting a decrease of 6.4% from the previous quarter (Q1FY26) where expenses were ₹23.07 crores. Year-over-year, total expenses rose by 7.8% from ₹20.03 crores in Q2FY25. The Earnings Per Share (EPS) was ₹2.71 in Q2FY26, showing a decrease of 16.6% quarter-over-quarter from ₹3.25 in Q1FY26. However, EPS improved significantly from a negative value of ₹-1.51 in Q2FY25, indicating a turnaround in earnings over the year. The financial data provided does not include information on other key financial ratios such as the P/E ratio, debt-to-equity ratio, or current ratio, which would typically be used to assess the company's financial health and operational efficiency.